Advisor Partners LLC raised its position in Pfizer Inc. (NYSE:PFE) by 5.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 120,607 shares of the biopharmaceutical company’s stock after purchasing an additional 6,091 shares during the period. Pfizer comprises approximately 0.8% of Advisor Partners LLC’s portfolio, making the stock its 18th biggest holding. Advisor Partners LLC owned 2,027.91% of Pfizer worth $4,306,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of PFE. Northstar Group Inc. boosted its stake in shares of Pfizer by 0.4% during the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 35 shares during the last quarter. Peregrine Asset Advisers Inc. boosted its stake in shares of Pfizer by 0.5% during the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 35 shares during the last quarter. Northwest Quadrant Wealth Management LLC boosted its stake in shares of Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 50 shares during the last quarter. River Wealth Advisors LLC boosted its stake in shares of Pfizer by 0.3% during the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 55 shares during the last quarter. Finally, Meridian Wealth Management LLC lifted its position in Pfizer by 0.5% during the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after buying an additional 57 shares during the period. 69.75% of the stock is currently owned by institutional investors.
Several equities analysts recently weighed in on the company. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Wednesday. Morgan Stanley set a $41.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, January 8th. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $37.98 target price on the stock. in a research report on Monday. Finally, Jefferies Group set a $40.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company. Pfizer currently has a consensus rating of “Buy” and an average target price of $38.94.
Pfizer Inc. (PFE) opened at $36.99 on Friday. The company has a market capitalization of $220,490.00, a PE ratio of 22.69, a PEG ratio of 2.45 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a twelve month low of $30.90 and a twelve month high of $37.37.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the business posted $0.61 EPS. equities research analysts anticipate that Pfizer Inc. will post 2.59 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.68%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is 78.53%.
Pfizer announced that its Board of Directors has approved a stock repurchase plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.
In related news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,450 shares of company stock worth $1,065,220. Company insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/19/advisor-partners-llc-boosts-holdings-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.